Sanara MedTech (SMTI)
NASDAQ:SMTI
Want to see SMTI full AI Analyst Report?
SMTI Stock Chart & Stats
$29.52
$0.13(0.40%)
At close: 4:00 PM EST
$29.52
$0.13(0.40%)
Day’s Range― - ―
52-Week Range$16.05 - $35.95
Previous CloseN/A
Volume5.72K
Average Volume (3M)61.65K
Market Cap
$200.60M
Enterprise Value$242.98M
Total Cash (Recent Filing)$13.59M
Total Debt (Recent Filing)$48.37M
Price to Earnings (P/E)81.5
Beta1.39
Next Earnings
Aug 17, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding9,163,969
10 Day Avg. Volume48,775
30 Day Avg. Volume61,645
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)33.96
Price to Sales (P/S)1.95
P/FCF Ratio93.17
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue2.26
Enterprise Value/Gross Profit2.48
Enterprise Value/Ebitda21.22
Forecast
1Y Price Target
$34.00Price Target Upside15.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.12
Revenue Forecast (FY)$117.30M
Bulls Say, Bears Say
Bulls Say
Commercial PartnershipVizient contract expands institutional access to BIASURGE through contracted pricing and pre-negotiated terms, supporting potential revenue acceleration as hospitals adopt the product.
Pipeline Differentiation And Regulatory ProgressOsStic's Breakthrough Device designation and preclinical data showing stronger bonding than traditional bone cement position it as a differentiated bone bioadhesive with potential to expand the company's addressable market.
Strategic Refocus And Margin ProfileDiscontinuation of the loss-making THP unit refocuses the company on a higher-margin, scalable surgical platform, improving operational efficiency and potential profitability.
Bears Say
Balance Sheet LeverageModest cash balances alongside significant long-term debt indicate leverage that may constrain financial flexibility and limit the ability to fund growth initiatives.
Legacy Cash DragThe discontinued THP unit had been loss-making and consumed cash, creating a legacy drag that could pressure liquidity during the transition to a focused surgical business.
Refinancing And Interest-rate SensitivitySignificant long-term debt increases exposure to refinancing risk and sensitivity to higher interest costs, which could strain resources if commercial ramp-up is slower than expected.
Sanara MedTech News
SMTI FAQ
What was Sanara MedTech’s price range in the past 12 months?
Sanara MedTech lowest stock price was $16.05 and its highest was $35.95 in the past 12 months.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market cap is $200.60M.
When is Sanara MedTech’s upcoming earnings report date?
Sanara MedTech’s upcoming earnings report date is Aug 17, 2026 which is in 89 days.
How were Sanara MedTech’s earnings last quarter?
Sanara MedTech released its earnings results on May 11, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.17.
Is Sanara MedTech overvalued?
According to Wall Street analysts Sanara MedTech’s price is currently Undervalued.
Does Sanara MedTech pay dividends?
Sanara MedTech does not currently pay dividends.
What is Sanara MedTech’s EPS estimate?
Sanara MedTech’s EPS estimate is -0.03.
How many shares outstanding does Sanara MedTech have?
Sanara MedTech has 9,163,969 shares outstanding.
What happened to Sanara MedTech’s price movement after its last earnings report?
Sanara MedTech reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went up 13.43%.
Which hedge fund is a major shareholder of Sanara MedTech?
Currently, no hedge funds are holding shares in SMTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanara MedTech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (15.18% Upside)
$34.00 (15.18% Upside)
Blogger Sentiment
Bullish
SMTI Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.65%
12-Months-Change
Fundamentals
Return on Equity
-246.44%
Trailing 12-Months
Asset Growth
-28.12%
Trailing 12-Months
Company Description
Sanara MedTech
Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.
SMTI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive picture: the company delivered strong top-line growth (19% YoY), improved margins, positive GAAP net income, and sizable adjusted EBITDA improvement while expanding commercial reach and reaffirming full-year guidance. Key concerns noted were modest cash reduction, higher interest/other expenses, increased SG&A, and that new sales hires and the Vizient contract will take time to be fully accretive. On balance, the positives (growth, profitability, margin expansion, distribution scale, and cash-based debt servicing) materially outweigh the headwinds.View all SMTI earnings summariesSMTI Stock 12 Month Forecast
Average Price Target
$34.00
▲(15.18% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sharps Technology, Inc.
―
Ownership Overview
3.28% Insiders
2.85% Mutual Funds
1.81% Other Institutional Investors
88.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---